KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2026)

AbCellera Biologics filings provide 7 years of Cash from Financing Activities readings, the most recent being $7.2 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 20.47% to $7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Mar 2026, down 3.8% year-over-year, with the annual reading at $14.1 million for FY2025, 10.28% up from the prior year.
  • Cash from Financing Activities hit $7.2 million in Q1 2026 for AbCellera Biologics, up from $4.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.4 million in Q3 2025 and bottomed at -$3.4 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $2.5 million, with a median of $2.8 million recorded in 2024.
  • The largest annual shift saw Cash from Financing Activities soared 34994.74% in 2023 before it tumbled 227.31% in 2025.
  • AbCellera Biologics' Cash from Financing Activities stood at $349000.0 in 2022, then soared by 978.8% to $3.8 million in 2023, then increased by 10.01% to $4.1 million in 2024, then decreased by 0.65% to $4.1 million in 2025, then soared by 74.78% to $7.2 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Cash from Financing Activities are $7.2 million (Q1 2026), $4.1 million (Q4 2025), and $7.4 million (Q3 2025).